Introduction. Thyroid dysfunction often develops gradually, and fatigue, weight change, or palpitations cannot reliably distinguish endocrine disease from other conditions. Laboratory biomarkers reveal disturbances before characteristic clinical findings become apparent. However, detecting a biochemical deviation does not automatically establish persistent disease or justify treatment. Clinical context determines whether an abnormal result represents gland failure, excess hormone production, physiological adaptation, or measurement error (Chaker et al., 2017; De Leo et al., 2016).
Methods. This focused narrative review integrates six established scholarly publications addressing diagnosis, subclinical disease, replacement therapy, and assay interference. The synthesis prioritizes decisions relevant to outpatient laboratories and primary care. It is neither a systematic review nor an experimental investigation; therefore, its conclusions summarize clinical principles rather than new estimates of diagnostic performance.
Results. Thyrotropin, commonly termed thyroid-stimulating hormone or TSH, is sensitive to small changes in circulating thyroid hormones. Elevated TSH with reduced free thyroxine supports overt primary hypothyroidism; suppressed TSH with elevated free thyroxine or triiodothyronine supports overt thyrotoxicosis. Abnormal TSH with normal free hormones defines a subclinical biochemical pattern, but persistence should be established when clinically appropriate. Progression and treatment decisions depend on abnormality severity, age, symptoms, pregnancy, and cardiovascular context (Biondi & Cooper, 2008).
Thyroid peroxidase antibodies identify autoimmune susceptibility and help estimate progression risk, particularly with elevated TSH. Positivity alone does not demonstrate impaired hormone production, and serial titers generally do not guide replacement dosing. Thyrotropin receptor antibodies support Graves disease diagnosis and can assist selected treatment and pregnancy decisions. Thyroglobulin is not a routine marker of thyroid functional status.
Discussion. During levothyroxine treatment for primary hypothyroidism, TSH is generally reassessed approximately four to six weeks after dose adjustment; stable patients require less frequent surveillance. In central hypothyroidism, free thyroxine rather than TSH guides biochemical assessment. Early antithyroid treatment monitoring requires free thyroxine and triiodothyronine because TSH suppression can persist despite improving hormone concentrations (Jonklaas et al., 2014; De Leo et al., 2016).
Pregnancy requires appropriate gestational reference intervals. Acute illness, medications, and inconsistent sampling relative to levothyroxine ingestion may complicate interpretation. Biotin and interfering antibodies can produce misleading immunoassay results. Unexpected biochemical combinations should prompt medication review, clinician–laboratory discussion, and, when indicated, testing with another analytical method (Favresse et al., 2018). A reflex strategy linking TSH to indicated hormone testing can conserve resources without replacing clinical judgment (Walsh, 2016).
Conclusion. Early diagnosis depends on selecting complementary biomarkers, confirming uncertain findings, and recognizing situations where TSH is insufficient. Longitudinal interpretation is more informative than isolated values. A coordinated laboratory and clinical approach supports timely diagnosis while limiting unnecessary investigations and inappropriate treatment.
1. Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017). Hypothyroidism. The Lancet, 390(10101), 1550–1562.
2. De Leo, S., Lee, S. Y., & Braverman, L. E. (2016). Hyperthyroidism. The Lancet, 388(10047), 906–918.
3. Biondi, B., & Cooper, D. S. (2008). The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews, 29(1), 76–131.
4. Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., & Sawka, A. M. (2014). Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid, 24(12), 1670–1751.
5. Favresse, J., Burlacu, M.-C., Maiter, D., & Gruson, D. (2018). Interferences with thyroid function immunoassays: Clinical implications and detection algorithm. Endocrine Reviews, 39(5), 830–850.
6. Walsh, J. P. (2016). Managing thyroid disease in general practice. Medical Journal of Australia, 205(4), 179–184.